If you are a person who is experiencing heart issues, they are about to end very soon. Novartis AG’s drug is a heart-failure preventer and it is almost here. It is on its way to be approved for European use by the end of 2015 and EU regulators approve of it to such high extent that they are all willing to back it up until the deed is done.
The drug is called Entresto, known in the medical world as LCZ696. It is the first drug in a few decades that can actually help patients who have a heart that cannot pump blood efficiently. The estimated sales are huge, specialists declaring that the drug might hit a $4.4 billion sale by the time it reaches 2020.
The only thing that stands in between Novartis AG and the drug’s release is an approval from the European Commission. Once the approval is given, the company will establish a price for the drug and proceed to commence sales, making the lives of thousands of people a lot easier with this miracle drug.
Dermot Doherty, Novartis’ spokesman declared that “prices in countries in Europe will be confirmed after EC approval and will be determined according to local pricing and reimbursement regulations, submissions and evaluation processes.”
Entresto has received numerous qualifications for its outstanding performance. Last week it obtained Switzerland’s approval and July marked the month in which it received approval from the U.S. FDA. Once the European Commission will give its final verdict, Entresto will soon be available for every patient in the world who has heart issues and wants to be rid of them.
When it was put to the test during its trials, Entresto has significantly reduced the risk of cardiovascular death. It also had an important impact on first-time hospitalizations resulted from heart failure. According to specialists, the drug reduced the number of hospitalizations by approximately 20%. This achievement set it miles ahead of generic medicine.
With performances like these, we expect Entresto to be one of the top selling medicines of the year 2016, with great potential of helping people and making money at the same time. We are looking forward to the approval form the European Commission so that thousands of people will be able to live with a better hear thanks to this extraordinary medical achievement.
Photo Credits deviantart.net